BioSpace News Archive

The report suggests that rising demand for international accreditations and result comparability by using high-throughput automated immunoassays is spurring the growth of chemiluminescence immunoassay (CLIA) analyzers in coming years (2017 to 2025).

The report suggests that rising demand for innovative technologies and adoption of rapid testing methods such as point of care testing is spurring the growth of meningitis diagnostic testing in coming years (2017 to 2025).

Pulse electromagnetic field therapy (PEMF) is a non-invasive treatment which creates micro-current in a tissue.

Glucose monitoring is a necessary step towards managing diabetes.

According to the report, the global testosterone replacement therapy market was valued at US$ 1,613.7 Mn in 2018 and is anticipated to expand at a CAGR of 4.4% from 2019 to 2027.

Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products including NIPT, commends the recent guideline update from the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) recommending that all pregnant patients be offered aneuploidy screening, regardless of age or risk factors. This rec

Acquisition will expand Cryoport’s presence in both the EMEA and APAC regions and broaden Cryoport’s range of temperature-controlled supply chain solutions for the life sciences; Upon closing, the acquisition is expected to be immediately accretive to earnings. [21-August-2020] NASHVILLE, Tenn. , Aug. 21, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”

Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel’s Board of Directors and granted as an inducement material to an employee’s employment with Rigel, in accordance with NASDAQ Lis

NANO-X IMAGING LTD (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today the pricing of its initial public offering of 9,178,744 ordinary shares at a price to the public of US$18 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nanox, are expected to be US$165.2 million. In addition, Nano

New analyses of the interim analysis data from the Phase 3 REGENERATE study describe the benefit of obeticholic acid (OCA) on noninvasive measures of liver fibrosis in NASH patients on treatment for at least 24 months Additional long-term data in PBC highlight the safety and durable efficacy of OCA through six years of open label treatment NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and